NO20032036L - Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser - Google Patents

Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser

Info

Publication number
NO20032036L
NO20032036L NO20032036A NO20032036A NO20032036L NO 20032036 L NO20032036 L NO 20032036L NO 20032036 A NO20032036 A NO 20032036A NO 20032036 A NO20032036 A NO 20032036A NO 20032036 L NO20032036 L NO 20032036L
Authority
NO
Norway
Prior art keywords
pentamidines
chlorpromazine
medications
combinations
treatment
Prior art date
Application number
NO20032036A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032036D0 (no
Inventor
Alexis Borixy
Curtis Keith
Michael A Foley
Brent R Stockwell
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of NO20032036D0 publication Critical patent/NO20032036D0/no
Publication of NO20032036L publication Critical patent/NO20032036L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20032036A 2000-11-06 2003-05-06 Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser NO20032036L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (fr) 2000-11-06 2001-10-30 Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques

Publications (2)

Publication Number Publication Date
NO20032036D0 NO20032036D0 (no) 2003-05-06
NO20032036L true NO20032036L (no) 2003-07-04

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032036A NO20032036L (no) 2000-11-06 2003-05-06 Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser

Country Status (29)

Country Link
US (4) US6569853B1 (fr)
EP (1) EP1339399B1 (fr)
JP (1) JP2004517915A (fr)
KR (1) KR100720205B1 (fr)
CN (1) CN1484525A (fr)
AR (1) AR035500A1 (fr)
AT (1) ATE318590T1 (fr)
AU (1) AU2002246636B8 (fr)
BG (1) BG107831A (fr)
BR (1) BR0115166A (fr)
CA (1) CA2436799C (fr)
CY (1) CY1105501T1 (fr)
DE (1) DE60117615T2 (fr)
DK (1) DK1339399T3 (fr)
EE (1) EE200300212A (fr)
ES (1) ES2258566T3 (fr)
HR (1) HRP20030460A2 (fr)
HU (1) HUP0400529A3 (fr)
IL (1) IL155795A0 (fr)
IS (1) IS2457B (fr)
MX (1) MXPA03003960A (fr)
NO (1) NO20032036L (fr)
NZ (1) NZ525773A (fr)
PL (1) PL362690A1 (fr)
PT (1) PT1339399E (fr)
RU (1) RU2286769C2 (fr)
SK (1) SK5452003A3 (fr)
TW (1) TWI259077B (fr)
WO (1) WO2002058684A2 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
DE10015818A1 (de) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor und Verfahren zum Ermitteln makromolekularer Biopolymere mit einem Biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
EP1360180A1 (fr) * 2001-01-19 2003-11-12 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (fr) * 2001-03-06 2002-09-12 Prendergast Patrick T Polytherapie pour la reduction de la toxicite d'agents chimiotherapeutiques
WO2002096412A1 (fr) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Inhibiteurs de ptpase et leur methode d'utilisation
FR2825279B1 (fr) * 2001-06-01 2005-04-08 Molecular Engines Lab Medicament utile dans le traitement du cancer
US7416723B2 (en) * 2001-09-07 2008-08-26 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
WO2003092616A2 (fr) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Compositions therapeutiques constituees de pentamidine et methodes d'utilisation de ces dernieres pour traiter le cancer
HRP20050115A2 (en) * 2002-07-11 2005-10-31 Combinatorx Combinations of drugs for the treatment of neoplasms
EP1606759B1 (fr) * 2003-03-26 2010-05-05 Synergy Biosystems Ltd. Procede d'identification d'agents biologiquement actifs et combinaisons synergiques
AU2004248187A1 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273910A1 (en) * 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
WO2005046694A1 (fr) * 2003-11-13 2005-05-26 Københavns Universitet Thioridazine et ses derives, utilises pour inverser la resistance aux medicaments antimicrobiens
WO2005070126A2 (fr) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Systemes et procedes pour le traitement de maladies inflammatoires et proliferantes humaines, et des plaies avec le gene ucp et/ou l'anticorps anti-fas ou autre inhibiteur, eventuellement avec un inhibiteur du metabolisme d'acide gras et/ou un inhibiteur du metabolisme de glucose et applications associees
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1984663A (zh) * 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
MXPA06012566A (es) 2004-04-30 2007-05-09 Bkg Pharma Aps Tratamiento de enfermedades infecciosas.
WO2005117847A2 (fr) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methodes et composes de traitement de neoplasmes
US20080269259A1 (en) * 2005-01-19 2008-10-30 The Trustees Of The University Of Pennsylvania Regulation of Autophagy and Cell Survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
EP1877060A2 (fr) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Systemes et procedes servant a traiter des maladies inflammatoires et proliferatives humaines, au moyen d'un compose qui inhibe le metabolisme des acides gras et la glycolyse
WO2006118821A2 (fr) * 2005-05-02 2006-11-09 The Regents Of The University Of Colorado Systemes et procedes de traitement de maladies inflammatoires et proliferatives humaines au moyen d'une combinaison de composes, ou d'un compose bifonctionnel inhibant le metabolisme des acides gras et la glycolyse
CA2601067A1 (fr) 2005-05-04 2006-11-09 Medigene Ag Methode d'administration d'une preparation liposomale cationique
DE102005024017A1 (de) * 2005-05-25 2006-11-30 Merck Patent Gmbh Chinazolinone
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2007082052A2 (fr) * 2006-01-11 2007-07-19 The Cleveland Clinic Foundation Compositions therapeutiques et procedes utilisables pour moduler les proteine-tyrosine-phosphatases
CA2646156C (fr) 2006-03-22 2016-05-24 Medigene Ag Traitement du cancer du sein avec = triple recepteur negatif =
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
WO2007149381A2 (fr) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions thérapeutiques et méthodes à utiliser dans le traitement du cancer
WO2008010223A2 (fr) * 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugués de gaba anti-douleur
WO2008080398A1 (fr) * 2007-01-05 2008-07-10 Bkg Pharma Aps Agents anti-infectieux tels que des dérivés de phénothiazine et de thioxanthène pour traiter les maladies infectieuses
CA2674891C (fr) * 2007-01-09 2016-03-15 Fovea Pharmaceuticals Appareil pour injection intra-oculaire
DE102007013854A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydrochinoline
DE102007013856A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydropyrrolochinoline
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
EP2194981B1 (fr) * 2007-10-05 2011-11-23 Université de Mons-Hainaut Bisbenzimidazoles en tant qu'agents antipaludiques
EP2550963B1 (fr) * 2011-07-25 2016-10-12 Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG Esters d'acide carboxylique d'amidoxime de la pentamidine en tant que prodrogues et leur utilisation comme médicament
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
WO2009148623A2 (fr) * 2008-06-05 2009-12-10 Stc.Unm Procédés et compositions associées pour le traitement du cancer
US20100035858A1 (en) * 2008-07-18 2010-02-11 Immune Control, Inc. Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
US8993625B2 (en) * 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
WO2010125462A2 (fr) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Combinaisons de pentamidine pour traiter le cancer
JP2012527231A (ja) 2009-05-20 2012-11-08 ユニヴァーシテ ド ジュネーヴ 癌開始細胞のミトコンドリア活性阻害剤及びその使用
US20120277193A1 (en) * 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
AU2010329440A1 (en) * 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
US20130165417A1 (en) * 2010-04-23 2013-06-27 University Of Florida Research Foundation Methods and compositions for treating ace2-related disorders
US8916610B2 (en) 2010-09-22 2014-12-23 Ramot At Tel-Aviv University Ltd. Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
WO2014086478A1 (fr) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibiteurs de la protéase malt1
MX2015007945A (es) * 2012-12-21 2016-02-16 Verlyx Pharma Inc Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
RU2530651C1 (ru) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, обладающее противовоспалительным и антифибротическим действием в легочной ткани при цитостатическом воздействии
KR101538264B1 (ko) * 2014-01-24 2015-07-20 계명대학교 산학협력단 티오리다진과 트레일을 유효성분으로 함유하는 암 예방 또는 치료용 약학조성물
EP3148547B1 (fr) * 2014-06-02 2024-01-03 National Yang-Ming University Procédé de traitement d'un cancer pharmacorésistant
CN105153042B (zh) * 2015-07-17 2017-11-24 四川大学 一种化合物及其在制备治疗可卡因成瘾的药物中的用途
US20210378992A1 (en) * 2018-10-19 2021-12-09 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN113766914B (zh) 2018-12-20 2024-02-13 美商奥润沙公司 戊烷脒的类似物和其用途
CN109793727A (zh) * 2019-03-13 2019-05-24 湖北科技学院 一种有效抗恶性肿瘤的药物组合物及其应用
KR102562739B1 (ko) * 2020-09-11 2023-08-03 연세대학교 산학협력단 암의 기원 세포의 사멸용 약학적 조성물
CN114588163B (zh) * 2020-12-04 2026-07-14 中国福利会国际和平妇幼保健院 盐酸氯丙嗪在治疗子宫内膜癌中的应用
KR102315103B1 (ko) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 티오리다진 및 퍼헥실린을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
GB1288376A (fr) 1968-10-29 1972-09-06
DE3827974A1 (de) 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6280768B1 (en) 1996-07-03 2001-08-28 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic protozoally induced diarrhea
US6008247A (en) 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ　ノルディスク　アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
ES2198139T3 (es) 1998-08-20 2004-01-16 The University Of North Carolina At Chapel Hill Compuestos de dibenzotiofeno y procedimientos de uso de los mismos.
JP2002524503A (ja) 1998-09-17 2002-08-06 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二陽イオン分子の抗真菌活性
JP3679943B2 (ja) * 1999-03-02 2005-08-03 大日本印刷株式会社 パターン形成体の製造方法
DK1231910T3 (da) 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
HRP20050115A2 (en) 2002-07-11 2005-10-31 Combinatorx Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050158320A1 (en) 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
DE60117615T2 (de) 2006-11-09
HUP0400529A3 (en) 2006-02-28
PT1339399E (pt) 2006-07-31
BR0115166A (pt) 2003-12-30
WO2002058684A3 (fr) 2003-04-17
WO2002058684A2 (fr) 2002-08-01
JP2004517915A (ja) 2004-06-17
EE200300212A (et) 2003-08-15
US20070099906A1 (en) 2007-05-03
AU2002246636B8 (en) 2006-01-19
HUP0400529A2 (hu) 2004-06-28
CA2436799A1 (fr) 2002-08-01
CA2436799C (fr) 2007-12-18
KR100720205B1 (ko) 2007-05-21
DK1339399T3 (da) 2006-06-19
US20030166642A1 (en) 2003-09-04
NZ525773A (en) 2005-04-29
KR20030048460A (ko) 2003-06-19
US6846816B2 (en) 2005-01-25
US20050192274A1 (en) 2005-09-01
AR035500A1 (es) 2004-06-02
ES2258566T3 (es) 2006-09-01
PL362690A1 (en) 2004-11-02
MXPA03003960A (es) 2004-09-10
IL155795A0 (en) 2003-12-23
CN1484525A (zh) 2004-03-24
TWI259077B (en) 2006-08-01
EP1339399A2 (fr) 2003-09-03
AU2002246636B2 (en) 2005-12-01
DE60117615D1 (de) 2006-04-27
EP1339399B1 (fr) 2006-03-01
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
SK5452003A3 (en) 2004-07-07
BG107831A (bg) 2004-02-27
CY1105501T1 (el) 2010-04-28
ATE318590T1 (de) 2006-03-15
NO20032036D0 (no) 2003-05-06
IS6806A (is) 2003-05-05
IS2457B (is) 2008-11-15
HRP20030460A2 (en) 2005-04-30
RU2286769C2 (ru) 2006-11-10

Similar Documents

Publication Publication Date Title
NO20032036D0 (no) Kombinasjoner av medikamenter (f.eks. klorpromazin og pentamidiner) for behandling av neoplastiske forstyrrelser
PT1313489E (pt) Composicoes farmaceuticas para o tratamento de mucosite, estomatite e sindroma de behcet
EP1363625A4 (fr) Combinaisons de medicaments (p. ex. un benzimidazole et pentamidine) dans le traitement de troubles neoplasiques
NO20052855D0 (no) Fosfonoksykinazolinderivater og farmasoytisk anvendelse derav.
ITFI20000154A0 (it) Convogliatore radioelettrico asimmetrico terapeutico.
PT1605956E (pt) Administração de capsaicinóides para o tratamento da osteoartrite
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
IS7137A (is) Samsett meðferð til meðhöndlunar á krabbameini
EP1299337A4 (fr) Hydroxyphenstatine et promedicaments associes
DK1041985T3 (da) Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
NO20023448D0 (no) Medikamentkombinasjon for behandling av depresjon og beslektede forstyrrelser omfattende mirtazapin
DE60216563D1 (de) Führungsdraht
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DE60203208D1 (de) Führungsdraht
NO308213B1 (no) Substituerte indanylidinacetylguanidiner, deres anvendelse og medikamenter inneholdende forbindelsene
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
DK1317478T3 (da) Skelnen mellem GnRH-I og GnRH-II
IS6619A (is) S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum
NO20026148L (no) Medisiner for forhindring og behandling av neurodegenerative sykdommer
NO20034785D0 (no) Farmasöytiske kombinasjoner basert på pyridoindolon-derivater og anticancermidler
BR0210635B1 (pt) produto absorvente.
NO20040935L (no) Plaster for behandling av dysfunksjoner og forstyrrelser i negler.
NO20006343D0 (no) Dreieanordning for möbler o.l.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application